Bioventus (NASDAQ:BVS) Shares Gap Down on Analyst Downgrade

Bioventus Inc. (NASDAQ:BVS)’s stock price gapped down before the market opened on Tuesday after Canaccord Genuity Group lowered their price target on the stock from $19.00 to $18.00. The stock had previously closed at $13.15, but opened at $11.02. Canaccord Genuity Group currently has a buy rating on the stock. Bioventus shares last traded at $11.1550, with a volume of 392,065 shares changing hands.

BVS has been the topic of a number of other reports. Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price target on shares of Bioventus in a research note on Thursday, August 6th. Weiss Ratings raised Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a research note on Monday, August 17th. Finally, Barrington Research set a $18.00 target price on Bioventus in a research report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, Bioventus has an average rating of “Buy” and a consensus price target of $16.60.

More Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported third-quarter adjusted EPS of $0.17, matching analyst expectations and increasing from $0.15 a year earlier. The result marked the company’s sixth consecutive quarterly EPS beat or in-line result. Bioventus Matches Q3 Earnings Estimates
• Positive Sentiment: Management reaffirmed its fiscal 2026 adjusted EPS outlook of $0.75 to $0.79, broadly consistent with the $0.78 consensus estimate. The company’s earnings performance also benefited from debt paydown and lower interest costs. Bioventus Fiscal 2026 Outlook
• Neutral Sentiment: Third-quarter revenue was $142.44 million, while return on equity was 28.08% and net margin was 9.36%. Investors are assessing whether improving profitability can offset slower top-line growth. Bioventus Reports Third Quarter Financial Results
• Negative Sentiment: Bioventus cut fiscal 2026 revenue guidance to $590 million-$595 million from a level implied by the prior outlook, below the $604.6 million consensus estimate. The reduction signals weaker operational growth and was the main source of investor pressure. Bioventus Sales Miss and Outlook Cut
• Negative Sentiment: Commentary characterized earnings growth as being driven more by debt reduction than by underlying operations, raising concerns about the sustainability of profit improvement if revenue momentum remains limited. Bioventus Earnings Growth and Revenue Outlook

Institutional Trading of Bioventus

A number of institutional investors have recently added to or reduced their stakes in the business. Covestor Ltd grew its position in Bioventus by 25.6% in the third quarter. Covestor Ltd now owns 5,808 shares of the company’s stock worth $79,000 after acquiring an additional 1,182 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Bioventus by 2,809.1% during the 3rd quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock valued at $26,000 after purchasing an additional 1,854 shares in the last quarter. Quantum Financial Partners LLC raised its holdings in shares of Bioventus by 11.8% during the 3rd quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company’s stock valued at $194,000 after purchasing an additional 1,500 shares in the last quarter. USA Financial Formulas bought a new position in shares of Bioventus during the 3rd quarter valued at $42,000. Finally, State of Alaska Department of Revenue lifted its stake in shares of Bioventus by 446.4% in the 3rd quarter. State of Alaska Department of Revenue now owns 18,953 shares of the company’s stock valued at $258,000 after purchasing an additional 15,484 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Stock Performance

The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.69. The firm’s 50 day moving average is $13.68 and its 200-day moving average is $10.90. The firm has a market cap of $930.54 million, a price-to-earnings ratio of 14.48, a price-to-earnings-growth ratio of 1.87 and a beta of 0.64.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.17. The firm had revenue of $142.44 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Sell-side analysts anticipate that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.

About Bioventus

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.